Akebia Therapeutics (AKBA) Equity Average (2016 - 2025)
Historic Equity Average for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $35.4 million.
- Akebia Therapeutics' Equity Average rose 18414.85% to $35.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.4 million, marking a year-over-year increase of 18414.85%. This contributed to the annual value of -$39.9 million for FY2024, which is 21462.1% down from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Equity Average is $35.4 million, which was up 18414.85% from $26.9 million recorded in Q2 2025.
- Akebia Therapeutics' Equity Average's 5-year high stood at $229.1 million during Q1 2021, with a 5-year trough of -$772.9 million in Q4 2022.
- Moreover, its 5-year median value for Equity Average was -$12.3 million (2025), whereas its average is -$49.7 million.
- In the last 5 years, Akebia Therapeutics' Equity Average plummeted by 83202.29% in 2022 and then skyrocketed by 18818.76% in 2025.
- Akebia Therapeutics' Equity Average (Quarter) stood at $105.6 million in 2021, then crashed by 832.02% to -$772.9 million in 2022, then skyrocketed by 95.47% to -$35.0 million in 2023, then crashed by 42.25% to -$49.8 million in 2024, then skyrocketed by 171.11% to $35.4 million in 2025.
- Its Equity Average stands at $35.4 million for Q3 2025, versus $26.9 million for Q2 2025 and -$12.3 million for Q1 2025.